ArticleGastroenterology2020
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment.
Article in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.Scientific reports · 2022Pooled it
- Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis.Proceedings of the National Academy of Sciences of the United States of America · 2021Pooled it
- The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review.PloS one · 2021Pooled it
- Review
- Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin.Frontiers in microbiology · 2022Review
- Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19.Gastroenterology research · 2021Article
- A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.Medicina (Kaunas, Lithuania) · 2021Article
- Intestinal ischemic manifestations of SARS-CoV-2: Results from the ABDOCOVID multicentre study.World journal of gastroenterology · 2021Article
- Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.The lancet. Gastroenterology & hepatology · 2021Observational
- Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2021Article
- Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2021Article
- COVID-19 in Immunosuppressed Children.Frontiers in pediatrics · 2021Review
- SARS-CoV-2 and the Gastrointestinal Tract in Children.Frontiers in pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.